KURA ONCOLOGY, INC. Additional Paid in Capital, Common Stock
KURA ONCOLOGY, INC. (KURA) had Additional Paid in Capital, Common Stock of $1.37 billion as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-12
- 2026-06-30: Additional Paid in Capital, Common Stock $1.37B.
- 2026-03-31: Additional Paid in Capital, Common Stock $1.36B.
- 2025-12-31: Additional Paid in Capital, Common Stock $1.35B.
- 2025-09-30: Additional Paid in Capital, Common Stock $1.33B.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $1.37B 10-Q · filed 2026-08-12 |
| 2026-03-31 | $1.36B 10-Q · filed 2026-05-12 |
| 2025-12-31 | $1.35B 10-Q · filed 2026-08-12 |
| 2025-09-30 | $1.33B 10-Q · filed 2025-11-04 |
| 2025-06-30 | $1.32B 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.32B 10-Q · filed 2025-05-01 |
| 2024-12-31 | $1.31B 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.30B 10-Q · filed 2024-11-07 |
| 2024-06-30 | $1.29B 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.28B 10-Q · filed 2024-05-02 |
| 2023-12-31 | $1.12B 10-K · filed 2025-02-28 |
| 2023-09-30 | $1.11B 10-Q · filed 2023-11-02 |
| 2023-06-30 | $1.10B 10-Q · filed 2023-08-09 |
| 2023-03-31 | $1.00B 10-Q · filed 2023-05-10 |
| 2022-12-31 | $997.11M 10-K · filed 2024-02-27 |
| 2022-09-30 | $964.72M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $957.49M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $948.31M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $941.36M 10-K · filed 2023-02-23 |
| 2021-09-30 | $934.17M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $925.80M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $919.26M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $913.35M 10-K · filed 2022-02-24 |
| 2020-09-30 | $582.61M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $574.38M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $434.72M 10-Q · filed 2020-05-04 |
| 2019-12-31 | $431.32M 10-K · filed 2021-02-24 |
| 2019-09-30 | $428.26M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $425.04M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $313.22M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $310.85M 10-K · filed 2020-02-25 |
| 2018-09-30 | $308.37M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $231.12M 10-Q · filed 2018-08-06 |
| 2018-03-31 | $228.76M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $169.20M 10-K · filed 2019-03-05 |
| 2017-09-30 | $167.75M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $112.87M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $111.65M 10-Q · filed 2017-05-15 |
| 2016-12-31 | $110.75M 10-K · filed 2018-03-12 |
| 2016-09-30 | $110.16M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $109.58M 10-Q · filed 2016-08-10 |
| 2016-03-31 | $108.97M 10-Q · filed 2016-05-11 |
| 2015-12-31 | $108.48M 10-K · filed 2017-03-14 |
| 2015-09-30 | $57.60M 10-Q · filed 2015-11-13 |
| 2015-06-30 | $57.07M 10-Q · filed 2015-08-14 |
| 2015-03-31 | $57.04M 10-Q · filed 2015-05-13 |
| 2014-12-31 | $238.00K 10-K · filed 2016-03-17 |
| 2013-03-31 | $49.50K 10-Q · filed 2013-05-15 |
| 2012-12-31 | $49.50K 10-Q · filed 2013-05-15 |
| 2012-09-30 | $49.50K 10-Q · filed 2012-11-14 |
| 2012-06-30 | $49.50K 10-Q · filed 2012-08-14 |
| 2012-03-31 | $49.50K 10-Q · filed 2012-05-15 |
| 2011-12-31 | $49.50K 10-K · filed 2013-03-28 |
| 2011-09-30 | $49.50K 10-Q · filed 2011-11-14 |
| 2011-06-30 | $49.50K 10-Q · filed 2011-08-15 |
| 2011-03-31 | $49.50K 10-Q · filed 2012-05-15 |
| 2010-12-31 | $49.50K 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |